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Abstract
Despite the well-known risks of smoking, policy, social pressure, and accessible cessation
programs, tens of millions of North American adults continue smoking rather than quitting or
switching to less harmful non-combustion nicotine products. We surveyed people smoking in
public in Edmonton, Canada (n = 242, year = 2007) to investigate smokers' reasons for resisting
switching to low-risk nicotine sources. 43% had used low-risk products (mostly pharmaceutical
nicotine). 75% indicated willingness to consider switching to low-risk products. Smokers cited
similar reasons for not switching to smokeless tobacco and pharmaceutical nicotine, largely based
on misinformation. Accurate risk information may lead many to try low-risk nicotine products.
Background
Despite massive education campaigns and legal restric-
tions, the prevalence of habitual nicotine use among
adults in Canada and the United States (US) remains at
about one quarter of the population, and most use the
deadliest source of nicotine, cigarettes [1-3]. Smokeless
tobacco (ST) causes roughly 1/100th the health risks of
smoking (see our website for more details: http://
www.tobaccoharmreduction.org) [4] and long term use
of pharmaceutical nicotine is believed to be similarly low
risk though we lack direct evidence, so can only extrapo-
late assuming the risks are similar to those from ST. Thus,
persuading smokers who cannot or will not quit using nic-
otine to switch to alternative sources is almost as benefi-
cial to their health as getting them to quit entirely. But
unlike in Sweden, where ST has largely replaced smoking
[5,6], there has been a very limited shift from smoked to
smokeless sources of nicotine in North America. Even
heavily-promoted pharmaceutical products have gener-
ated limited interest. For example, only 25% of partici-
pants in a national sample of adult smokers in the United
States had ever used nicotine patches and 22% had ever
tried nicotine gum, despite the fact that about 95% of par-
ticipants were aware of these products [7].
One of the barriers to smoking cessation via product
switching is misinformation about ST and pharmaceutical
nicotine products. Most (67%) people in a telephone sur-
vey in the US [8] and 59.8% of a sample of nurses [9] mis-
takenly believed that nicotine is the main cause of
tobacco-related cancers. Surveys of smokers and college
students in North America found that fewer than 15%
realize that ST is less harmful than smoking [10-12]. In
addition, a study found that most (75%) male US military
recruits believe that switching from smoking to ST does
not reduce tobacco users' risk [13]. Many smokers have
similar misconceptions about the health risks from using
pharmaceutical nicotine products [7,8]. The present study
was designed to specifically investigate smokers' amena-
bility to harm-reducing product switching, including con-
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sideration of switching to ST and pharmaceutical nicotine
and potential willingness to switch in the future, as well as
to partially assess the informational barriers to switching.
Methods
The research team enrolled a convenience sample of adult
smokers in public outdoor areas in Edmonton, Alberta
where people were smoking during five days in September
2007. The public outdoor areas included designated
smoking areas outside of office buildings, shopping malls,
bars, restaurants and construction sites. The researchers
systematically approached the first person they saw smok-
ing or starting to smoke upon completing the previous
survey. While the exact population we sampled from is
difficult to define, this was intended to provide a reason-
able cross-section of the target population for our harm
reduction education efforts in Edmonton; adult smokers
who are literate in English and engaged in civic life.
Our plan had been for the survey to precede the launch of
a harm-reduction-based marketing effort for a new ST
product in Edmonton. The survey was conducted shortly
after the product rollout due to delays by the university
health research ethics board which approved the study.
However, limited marketing preceded the survey and
there was limited awareness of the new product, so we do
not believe that the product launch had a major impact on
subjects' perceptions.
Upon confirming that potential participants were at least
18 years old, they were given an information sheet
explaining the survey and their rights as a research partic-
ipant. People who were eligible and agreed to participate
completed a one-page, anonymous, self-administered sur-
vey. The researchers read the survey to people who wished
to complete the survey but were visually impaired or indi-
cated that they could not complete a self-administered
survey. The research team defined terms on the survey,
such as snus and medicinal nicotine, if the participants
indicated that they did not understand them. Four hun-
dred thirteen adult smokers were approached, 242 of
whom completed the survey (response rate: 59%).
The survey assessed participants' use of cigarettes, ST and
pharmaceutical nicotine; reasons for not switching to ST
or pharmaceutical nicotine for harm reduction; and inter-
est in using hypothetical reduced harm nicotine products.
Some questions were based on the common beliefs and
misperceptions about tobacco and nicotine that are
reported in the literature or that we have observed in our
experience as educators. To assess the stated willingness to
switch to a reduced harm product with minimal misinfor-
mation baggage, we asked participants if they would con-
sider switching from smoking to two hypothetical
products; those products were described as providing nic-
otine in a way that was almost as satisfying as smoking
and could be used without anyone noticing, with one
reducing the health risks by 99% and the other by 50%.
The subjects were never told that the "hypothetical" 99%-
reduction product described existing ST products, nor was
any other potentially persuasive information offered.
Extensive epidemiological evidence shows that this is a
good approximation of the comparative risk for ST, and
many smokers have found the products to be a satisfying
substitute source of nicotine. Though there are no useful
epidemiological studies about long-term use of pharma-
ceutical nicotine, there is no reason to believe that these
products pose greater risk than ST, so this can be used as a
best guess about their effects also. Approved usage of exist-
ing pharmaceutical products is usually judged to be a poor
substitute in terms of nicotine delivery for tobacco harm
reduction. However, electronic cigarettes, which were not
yet well-known at the time of the survey, are quite liked by
many smokers. The survey and data are available at http:/
/www.tobaccoharmreduction.org/research/
smokersurveysept07.htm
SAS (version 9.1, SAS Institute, Cary, North Carolina) was
used for data cleaning and analysis. Our analysis method-
ology called for simply reporting univariate summaries of
responses as well as the bivariate analysis that appears
below. Male and female participants were compared. We
also compared reasons why participants did not previ-
ously consider switching to safer nicotine products and
their willingness to consider the hypothetical products.
Tests of statistical significance were not presented because
these are only appropriate when the purpose of a study is
to test a hypothesis rather than estimate prevalence. We
present 95% confidence intervals (CIs) to give readers an
indication of the robustness of the results but remind
readers that interpretation of these is still only indicative
of random error. In surveys such as this, and indeed most
epidemiology, the largest sources of error when extrapo-
lating the results to some population of interest are likely
non-random, such as systematic differences between the
study sample and target population and measurement
error, including misinterpretation of survey questions and
misclassification due to provision of answers that are per-
ceived to be "correct" or socially desirable.
Results and discussion
The results appear in Tables 1, 2 and 3. Participants' cur-
rent smoking status was based on observing them smok-
ing before, during, or soon after completing the survey.
Their demographic characteristics and their history of
using nicotine products are described in Table 1. Overall,
43% of participants had used low-risk nicotine products
(mostly pharmaceutical nicotine products). Four people
had attempted to use ST as a smoking cessation method.
Most participants had previously attempted cessation or
stated an expectation of quitting in the future. This survey
of current smokers obviously could offer no assessment ofHarm Reduction Journal 2009, 6:14 http://www.harmreductionjournal.com/content/6/1/14
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successful cessation. Reported average consumption was
15 cigarettes per day. (The midpoint was used for partici-
pants who entered a range. Two responses given in packs-
per-day were converted by multiplying by 20, though the
number of cigarettes per pack in Canada varies.)
Smokers' attitudes towards pharmaceutical nicotine prod-
ucts and ST are described in Table 2. Only 10% of those
surveyed had considered switching to ST, and 40% had
ever considered switching to pharmaceutical nicotine
products. Those who had never considered switching to
these products were asked to specify why not. The reasons
given by those who had not considered switching to phar-
maceutical nicotine products and ST were similar. The
most common reasons given for not switching to either ST
or pharmaceutical nicotine are popular fallacies. For
example, many participants did not switch to safer prod-
ucts because they believed that tobacco or nicotine in any
form is as harmful as smoking and that ST is more likely
to cause oral cancer than smoking. This is consistent with
a previous study in which university students who
smoked attributed a mean of 16% of the risks of cigarettes
to nicotine and 48% believed that ST definitely causes oral
cancer (Geertsema K, Phillips CV, Heavner K. University
Student Smokers' Perceptions of Risks and Barriers to
Harm Reduction, Submitted, Available at: http://tobacco
harmreduction.org/wpapers/001.htm).
In response to the questions about the hypothetical
reduced risk products, most participants (73%) were will-
ing to consider switching to a product that is almost as sat-
isfying as smoking but with 99% less risk than smoking
(Figure 1). This is consistent with results from the afore-
mentioned survey of student smokers, in which 64%
would consider switching to a product with 1% of the
health risks of smoking cigarettes (Geertsema K, Phillips
CV, Heavner K. University Student Smokers' Perceptions
of Risks and Barriers to Harm Reduction, Submitted,
Available at: http://tobaccoharmreduction.org/wpapers/
001.htm). As discussed earlier, the hypothetical was
Table 1: Participants' Demographic Characteristics and Usage of Products Containing Nicotine
Age
Mean (95% CI) 38 (36, 40)
Median (range) 39 (18–67)
n%
Male 106 44%
Approximate number of cigarettes currently smoked per day
Mean (95% CI) 15 (14, 16)
Median (range) 15 (0–50)
Used smokeless tobacco at least 10 times
Yes 25 11%
No 207 89%
Used pharmaceutical nicotine at least 10 times
Yes 84 36%
No 152 64%
Ever tried to quit smoking
Yes 217 90%
No 24 10%
Cessation methods that smokers previous tried1
Stopped all at once ("cold turkey") 163 67%
Gradually decreased the number of cigarettes smoked 120 50%
Counselling or a stop-smoking clinic or program 14 6%
Switched to chewing tobacco or snuff 42 %
Medicinal nicotine products 84 35%
Zyban/Wellbutrin/Buproprion or other medication 61 25%
Other methods 20 8%
Expect to quit smoking within the next 2 years
Yes 162 71%
No 65 29%
1Limited to participants who ever tried to quit smoking.Harm Reduction Journal 2009, 6:14 http://www.harmreductionjournal.com/content/6/1/14
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intended to describe modern Western ST products. The
description may overstate the satisfaction from most cur-
rent pharmaceutical nicotine products, which are less sat-
isfying substitutes for smoking than ST due to the higher
price and slower delivery of nicotine if used as directed,
but might apply to electronic cigarettes.
Few participants indicated that a 99% reduction in risk,
but not a 50% reduction, would be worth considering. We
did not attempt to tease out exactly how much reduction
in risk was necessary to attract someone to consider
switching, but merely wanted a very rough idea of
whether respondents were very sensitive to the magnitude
of the reduction. The answer was, with appropriate rough-
ness, they were not very sensitive. Five people indicated
that they were willing to switch to a product that reduced
their risks by 50% but not to a 99% reduced risk product,
possibly indicating a general innumeracy but possibly
suggesting that the quantified reduced risk was misunder-
stood as the remaining risk, suggesting that care be taken
when designing similar questions for future instruments.
We did not attempt to further interpret the answers sepa-
rately. Participants who were willing to consider switching
to hypothetical products that were either 50% or 99% less
harmful than smoking were classified as willing to con-
sider switching in the remainder of the analysis.
There were several noteworthy differences between the
male and female smokers in the sample. Female smokers
were less likely to have used ST (5%, 95% CI: 1%, 8% ver-
sus 18%, 95% CI: 11%, 26%) and more likely to have
used pharmaceutical nicotine at least 10 times (43%, 95%
CI: 34%, 51% versus 26%, 95% CI: 18%, 35%), compared
to males. Similarly, females were more likely to have con-
sidered switching to pharmaceutical nicotine than males
(47%, 95% CI: 39%, 55% and 30%, 95% CI: 21%, 39%,
respectively) and less likely to have considered switching
to ST (8%, 95% CI: 3%, 12% and 14%, 95% CI: 7%, 20%,
respectively). Many subjects who had not previously con-
sidered using ST had not consider switching because they
believed it to be socially unacceptable or gross (44%, 95%
CI: 35%, 53% of women and 36%, 95% CI: 26%, 46% of
Table 2: Barriers to Using Less Harmful Sources of Nicotine
Smokeless tobacco
(n = 236)
Pharmaceutical nicotine products
(n = 236)
Smokeless tobacco or pharmaceutical 
nicotine products
(n = 234)
% Yes (95% CI) % Yes (95% CI) % Yes (95% CI)
Never considered quitting smoking, but 
continuing to use nicotine, by switching from 
smoking to this product?
90% (86%, 94%) 60% (54%, 66%) 56% (50%, 62%)
Reasons for not considering switching1 (n = 212) (n = 142) (n = 131)
I believe that using tobacco in any form is as 
bad for you as smoking.
49% (42%, 56%) NA NA
I believe that using nicotine in any form is as 
bad for you as smoking.
42% (35%, 49%) 43% (35%, 51%) 51% (43%, 60%)
I believe that using smokeless tobacco is 
socially unacceptable or gross (because you 
have to spit or it makes a mess in your 
mouth).
41% (34%, 47%) NA NA
There are things I enjoy about smoking 
besides just getting nicotine.
35% (28%, 41%) 33% (25%, 41%) 43% (34%, 51%)
I believe that smokeless tobacco would 
increase my risk of oral (mouth) cancer.
34% (28%, 40%) NA NA
I believe that these products are more likely 
to cause addiction than smoking.
14% (9%, 19%) 14% (8%, 20%) 22% (15%, 29%)
Smokeless tobacco is hard to use. 11% (7%, 16%) NA NA
Smoking is important to my social life. 10% (6%, 14%) 8% (4%, 13%) 12% (7%, 18%)
I tried these products but I did not find them 
satisfying.
3% (1%, 6%) 9% (4%, 14%) 11% (5%, 16%)
The labels on medicinal products say they 
should only be used for a limited period of 
time.
NA 6% (2%, 9%) NA
Medicinal nicotine products are too 
expensive.
NA 5% (1%, 8%) NA
1Limited to participants who never considered switching from smoking to this product.
NA – Not applicable.Harm Reduction Journal 2009, 6:14 http://www.harmreductionjournal.com/content/6/1/14
Page 5 of 8
(page number not for citation purposes)
men). This reflects a lack of awareness about modern ST
products, which can be used invisibly and without spit-
ting. The difference between women and men probably
reflects differing aversions to spitting rather than differing
knowledge.
Males were more likely than females to have been deterred
from switching to ST in the past because they believed that
it is more addictive (19%, 95% CI: 11%, 28% versus 11%,
95% CI: 5%. 16%) and more likely to cause oral cancer
(39%, 95% CI: 28%, 49% versus 31%, 95% CI: 23%,
39%) compared to smoking. Female smokers were more
likely than males to consider switching to a reduced harm
product; though this disparity was not great. Seventy-eight
percent (95% CI: 71%, 85%) of females and 70% (95%
CI: 61%, 79%) of males indicated that they would con-
sider switching to a hypothetical reduced risk nicotine
product. This result is interesting since in Sweden males
have proven considerably more willing to switch [5,6].
Although no socioeconomic data was collected on the sur-
vey, the research team noted that a large proportion of the
male smokers appeared to be construction and trades
workers and a large proportion of the female smokers
worked in downtown office buildings. The effect of these
differences on the variations between the male and female
smokers in this sample is unknown.
Participants' reasons for not previously switching to ST
were associated with their willingness to consider switch-
ing to the hypothetical reduced risk nicotine products
(Table 3). Those who had previously attempted to switch
products were more likely to consider switching to the
hypothetical product, as were those who had not tried to
switch because of misperceptions about the health risks or
addiction. Contrary to expectations, subjects' stating that
there were factors other than nicotine that they liked
about smoking seemed to have little effect on their will-
ingness. There was a stronger association with stating that
smoking was important to one's social life (though there
were few who said yes to this). Seventy-nine percent of
people who had not switched to ST because of concerns
about social acceptability indicated that they would con-
sider switching to hypothetical products that could be
used discretely. Most (81%) of the smokers who did not
switch to ST because they believe that it causes oral cancer
were willing to consider switching to the hypothetical
Table 3: Variation in willingness to switch to "hypothetical" reduced risk nicotine products between those who did and did not cite 
particular reasons for not previously switching to safer products
% would consider switching to a hypothetical reduced 
risk nicotine product in the future 2
Reasons for not previously considering switching to ST or pharmaceutical nicotine to 
stop smoking but continuing to use nicotine1
(n = 130)
I tried switching to ST/pharm. nicotine but did not find it satisfying. Yes 79% (57%, 100%)
No 59% (51%, 68%)
I believe ST/pharm. nicotine is likely to cause addiction than smoking. Yes 69% (52%, 86%)
No 59% (50%, 69%)
I believe that nicotine in any form is as bad as smoking. Yes 67% (55%, 78%)
No 56% (44%, 68%)
There are things I enjoy about smoking besides just getting nicotine. Yes 60% (47%, 73%)
No 63% (52%, 74%)
Smoking is important to my social life. Yes 47% (21%, 72%)
No 63% (55%, 72%)
Reasons for not previously considering switching to ST to stop smoking but 
continuing to use nicotine1
(n = 211)
I believe that using tobacco in any form is as bad for you as smoking. Yes 76% (68%, 84%)
No 70% (61%, 79%)
I believe that using smokeless tobacco is socially unacceptable or gross 
(because you have to spit or it makes a mess in your mouth).
Yes 79% (70%, 88%)
No 69% (61%, 76%)
I believe that smokeless tobacco would increase my risk of oral (mouth) 
cancer.
Yes 81% (71%, 90%)
No 69% (61%, 77%)
Smokeless tobacco is hard to use. Yes 83% (67%, 98%)
No 72% (65%, 78%)
1Limited to smokers who had not previously considered switching to ST/pharmaceutical nicotine and responded to the questions about whether 
they would consider switching to hypothetical reduced risk nicotine products in the future.
2Would consider switching to a nicotine product that is 50% or 99% less harmful than cigarettes.Harm Reduction Journal 2009, 6:14 http://www.harmreductionjournal.com/content/6/1/14
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reduced risk product. This is consistent with the theory
that smokers' reluctance to switch is attributable to erro-
neous beliefs about ST. In addition, 79% (95% CI: 73%,
85%) of smokers who expected to quit in the next two
years would consider switching to the hypothetical
reduced risk product, compared to 65% (53%, 77%) of
smokers who did not expect to quit in the next two years.
Conclusion
This study suggests that many adult smokers are interested
in switching to safer forms of nicotine. While precise esti-
mates from this small convenience sample would be inap-
propriate, the responses are consistent with reports of
misperceptions about nicotine and tobacco in the litera-
ture, and strongly suggest that those misperceptions are
major barriers to harm reduction. The failure to have
already switched to existing low risk products, when con-
trasted with the willingness to switch to hypothetical
products, seems largely explained by erroneous beliefs
that tobacco and nicotine use are as inherently harmful as
smoking. There was some evidence of dissatisfaction with
existing alternatives, though much of the stated dissatis-
faction about ST products further indicated erroneous
beliefs about those products. It is true that nicotine prod-
ucts have non-nicotine aspects, such as flavor, physical
comfort, ritual, and consumer self-identity, which make
all substitutes for cigarettes imperfect, and it may be that
consumers answering a hypothetical question do not rec-
ognize the impact of switching on these habits. On the
other hand, the wide variety of low-risk products offer
many options, and people often find it much easier to
become used to a new ritual or habit than they think
This survey suggests that the barriers to switching are sim-
ilar for ST and pharmaceutical nicotine, a somewhat
ironic result. The widespread failure to understand that
non-combustion nicotine sources pose a tiny fraction of
the risk from smoking is largely attributable to the effec-
tive long-running disinformation campaign by anti-ST
and anti-harm-reduction activists who are more con-
cerned with promoting nicotine abstinence than public
health [14,15]. These anti-tobacco lobbyists usually do
Willingness to switch to reduced harm nicotine products (n = 238) Figure 1
Willingness to switch to reduced harm nicotine products (n = 238).
25%
65%
8%
2%
Would not consider switching
Would consider switching, regardless of 
whether product is  50% or 99% less harmful
Would switch, but only if 99% less harmful
Would only consider if 50% less harmful 
(apparently misunderstood the question)
Based on participants' responses to the following 2 questions (one included 99% and one included 50%):
If a new product provided nicotine in a way that was almost as satisfying as smoking, could be used without anyone noticing that you 
were using it and reduced your health risks by [99%] [50%], would you consider switching to this product? 
Harm Reduction Journal 2009, 6:14 http://www.harmreductionjournal.com/content/6/1/14
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not oppose pharmaceutical nicotine use, and indeed usu-
ally actively promote it. Ironically our results suggest that
the anti-harm-reduction, "quit or die" messages have
spilled over from ST to pharmaceutical nicotine, and have
been equally effective in misleading smokers about the
risks of both product types. This is an example of a general
cautionary lesson: when opinion leaders manipulate peo-
ple into doing something for reasons other than the real
motives of the leaders (such as avoiding ST because of
false beliefs about risk, rather than sharing their general
despite of tobacco), the short-run results may be what the
leaders intended, but the long run results will likely drift
far from that.
Despite the disinformation, the survey suggests there is
still great potential for tobacco harm reduction, making it
probably the most significant untried public health inter-
vention available in the West. Subjects who tried to switch
before were not deterred from trying again and may be the
most promising targets for encouragement to take this
important step to improving their health. Multiple
attempts and periodic relapses are common in the adop-
tion of other safer behaviors such as safer sex, increasing
physical activity and healthier eating. Anecdotal evidence
from Sweden suggests that switching is very often success-
ful as a gradual and non-monotonic process.
It appears that education about health risks and (particu-
larly for women) the discreteness of modern ST products
could lead a substantial portion of the smoking popula-
tion to try switching. While the number who might actu-
ally make the effort to switch upon learning the truth
would likely not be as high as those who were willing to
effortlessly say "yes" to the hypothetical product, even a
fairly small portion of that would represent millions of
smokers. If efforts to actively convince smokers that there
is no opportunity for harm reduction were to end, we
would expect to see the change begin. If the resources that
are currently devoted to misleading smokers about harm
reduction were instead targeted at informing them that
they have satisfying choices that are almost as good for
their health as quitting entirely, a very large change could
happen quite rapidly.
Abbreviations
ST: Smokeless tobacco.
Competing interests
The authors are interested in encouraging tobacco harm
reduction (reducing the morbidity and mortality caused
by tobacco use by encouraging smokers to switch to
smokeless tobacco or other low-risk alternatives). As a
result, they have an interest in doing research like this that
explores factors that make tobacco harm reduction more
or less likely to work. In addition to this actual substantial
interest, the authors also have what some mistakenly con-
sider to be the only real conflict of interest, funding from
the private sector: Dr. Phillips and his research group
(including Dr. Heavner and Mr. Rosenberg) are partially
supported by an unrestricted (completely hands-off)
grant to the University of Alberta from U.S. Smokeless
Tobacco Company. The grantor is unaware of this study,
and thus had no scientific input or other influence on it.
Dr. Phillips has consulted for U.S. Smokeless Tobacco
Company in the context of product liability litigation and
subsequent to the completion of this paper became a
member of British American Tobacco's External Scientific
Panel advising on issues of tobacco harm reduction. Dr.
Heavner owns a small amount of stock in Johnson &
Johnson. Though these do and might (respectively) repre-
sent interests, and credibly influence what  research we
consider important, our interest in accurately assessing
the barriers to harm reduction means it is not clear to us
how these interests might be seen as justifying the knee-
jerk accusation of bias – that we somehow altered the
presentation of these results based on non-scientific inter-
ests – that we often face from the political activists who
work to influence the science in this area.
Authors' contributions
KH designed the survey. Data collection was conducted by
KH, ZR and other students and researchers in CVP's
research group. CVP supervised data collection and analy-
sis. KH and ZR conducted the data analysis. All authors
contributed to writing the manuscript and have read and
approved the final manuscript.
References
1. Hammond D: Smoking behaviour among young adults:
beyond youth prevention.  Tob Control 2005, 14:181-185.
2. Lee DJ, Fleming LE, Arheart KL, LeBlanc WG, Caban AJ, Chung-
Bridges K, et al.:  Smoking rate trends in U.S. occupational
groups: the 1987 to 2004 National Health Interview Survey.
J Occup Environ Med 2007, 49:75-81.
3. Tanuseputro P, Manuel DG, Leung M, Nguyen K, Johansen H: Risk
factors for cardiovascular disease in Canada.  Can J Cardiol
2003, 19:1249-1259.
4. Phillips CV, Rabiu D, Rodu B: Calculating the comparative mor-
tality risk from smokeless tobacco versus smoking.  American
Journal of Epidemiology 2006, 163:S189.
5. Rodu B, Stegmayr B, Nasic S, Asplund K: Impact of smokeless
tobacco use on smoking in northern Sweden.  J Intern Med
2002, 252:398-404.
6. Stegmayr B, Eliasson M, Rodu B: The decline of smoking in north-
ern Sweden.  Scand J Public Health 2005, 33:321-324.
7. Bansal MA, Cummings KM, Hyland A, Giovino GA: Stop-smoking
medications: who uses them, who misuses them, and who is
misinformed about them?  Nicotine Tob Res 2004, 6(Suppl
3):S303-S310.
8. Cummings KM, Hyland A, Giovino GA, Hastrup JL, Bauer JE, Bansal
MA: Are smokers adequately informed about the health risks
of smoking and medicinal nicotine?  Nicotine Tob Res 2004,
6(Suppl 3):S333-S340.
9. Borrelli B, Novak SP: Nurses' knowledge about the risk of light
cigarettes and other tobacco "harm reduction" strategies.
Nicotine Tob Res 2007, 9:653-661.
10. O'Connor RJ, Hyland A, Giovino GA, Fong GT, Cummings KM:
Smoker awareness of and beliefs about supposedly less-
harmful tobacco products.  Am J Prev Med 2005, 29:85-90.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Harm Reduction Journal 2009, 6:14 http://www.harmreductionjournal.com/content/6/1/14
Page 8 of 8
(page number not for citation purposes)
11. O'Connor RJ, McNeill A, Borland R, Hammond D, King B, Boudreau
C, et al.: Smokers' beliefs about the relative safety of other
tobacco products: findings from the ITC collaboration.  Nico-
tine Tob Res 2007, 9:1033-1042.
12. Smith SY, Curbow B, Stillman FA: Harm perception of nicotine
products in college freshmen.  Nicotine Tob Res 2007, 9:977-982.
13. Haddock CK, Lando H, Klesges RC, Peterson AL, Scarinci IC: Modi-
fied tobacco use and lifestyle change in risk-reducing beliefs
about smoking.  Am J Prev Med 2004, 27:35-41.
14. Phillips CV, Wang C, Guenzel B: You might as well smoke; the
misleading and harmful public message about smokeless
tobacco.  BMC Public Health 2005, 5:31.
15. Phillips CV, Bergen P, Guenzel B: Persistent misleading health
advice about smokeless tobacco on the Web.  Poster presenta-
tion at the 11th World Congress on Internet in Medicine, Toronto, Canada
2006.